Rapport Therapeutics CDO Sells $808,844 in Stock Following Positive Clinical Results

Key Facts

Yeleswaram Krishnaswamy, the Chief Development Officer of Rapport Therapeutics, has sold 20,225 shares of common stock in a transaction valued at approximately $808,844. The sale, executed on April 17, 2026, was conducted under a pre-arranged Rule 10b5-1 trading plan, which typically indicates non-discretionary timing. This insider activity follows the company's recent announcement of positive Phase 2a trial results for its epilepsy drug candidate, RAP-219. While executive sales can sometimes signal caution, analysts remain largely positive on the firm's clinical pipeline and developmental milestones. Market data suggests the stock has seen significant momentum, though some indicators point toward a potential overvaluation following the clinical success. Investors continue to weigh these insider transactions against the robust fundamental progress of the company's lead neurological programs.